RESPOND3 - Responsible early Digital Drug Discovery

We aim to find new antibiotics and therapies for Chronic Obstructive Pulmonary Disease through the development of improved high-throughput computational methods. The project is built on a foundation of responsible research and innovation principles to align research objectives, processes, and outcomes with societal expectations.

In order to maintain the high health standards our society is accustomed to, there is an increasing need for innovations in drug discovery. The development of a new drug takes 15-20 years and costs billions of dollars. Without a more efficient path to drug discovery, many promising candidates will be lost in the “valley of death” and fail to be transformed into a drug that can benefit the public. RESPOND3 is developing a new high-throughput computational method to accurately identify candidates early in the discovery process. Through this project, we aim to discover and develop new antibiotics and better therapies to treat Chronic Obstructive Pulmonary Disease. The project design will be informed by the principles of responsible research and innovation through a sustainable and balanced stakeholder engagement framework. This project is funded by the Research Council of Norway and is one of the multidisciplinary research projects within Centre for Digital Life Norway.














Name Title Image
Sheikh, Zainab Afshan Assistant Professor Billede af Sheikh, Zainab Afshan

External researchers:


The Research Council of Norway logo
RESPOND3 - Responsible early Digital Drug Discovery has received a four year funding from The Research Council of Norway

Project: Towards better computational approaches and responsible innovation strategies in early drug discovery - application to antibiotics and COPD
(Grant number: 294594)

Period: 01.01.2019 to 31.08.2023


Helen YuPI External Researcher
Helen Yu